Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 1997 Jan 1;321(Pt 1):165–175. doi: 10.1042/bj3210165

Challenge of human Jurkat T-cells with the adenylate cyclase activator forskolin elicits major changes in cAMP phosphodiesterase (PDE) expression by up-regulating PDE3 and inducing PDE4D1 and PDE4D2 splice variants as well as down-regulating a novel PDE4A splice variant.

S Erdogan 1, M D Houslay 1
PMCID: PMC1218051  PMID: 9003416

Abstract

The cAMP phosphodiesterase (PDE) 3 and PDE4 isoforms provide the major cAMP-hydrolysing PDE activities in Jurkat T-cells, with additional contributions from the PDE1 and PDE2 isoforms. Challenge of cells with the adenylate cyclase activator forskolin led to a rapid, albeit transient, increase in PDE3 activity occurring over the first 45 min, followed by a sustained increase in PDE3 activity which began after approximately 3 h and continued for at least 24 h. Only this second phase of increase in PDE3 activity was blocked by the transcriptional inhibitor actinomycin D. After approximately 3 h of exposure to forskolin, PDE4 activity had increased, via a process that could be inhibited by actinomycin D, and it remained elevated for at least a 24 h period. Such actions of forskolin were mimicked by cholera toxin and 8-bromo-cAMP. Forskolin increased intracellular cAMP concentrations in a time-dependent fashion and its action was enhanced when PDE induction was blocked with actinomycin D. Reverse transcription (RT)-PCR analysis, using generic primers designed to detect transcripts representing enzymically active products of the four PDE4 genes, identified transcripts for PDE4A and PDE4D but not for PDE4B or PDE4C in untreated Jurkat T-cells. Forskolin treatment did not induce transcripts for either PDE4B or PDE4C; however, it reduced the RT-PCR signal for PDE4A transcripts and markedly enhanced that for PDE4D transcripts. Using RT-PCR primers for PDE4 splice variants, a weak signal for PDE4D1 was evident in control cells whereas, in forskolin-treated cells, clear signals for both PDE4D1 and PDE4D2 were detected. RT-PCR analysis of the PDE4A species indicated that it was not the PDE4A isoform PDE-46 (PDE4A4B). Immunoblotting of control cells for PDE4 forms identified a single PDE4A species of approximately 118 kDa, which migrated distinctly from the PDE4A4B isoform PDE-46, with immunoprecipitation analyses showing that it provided all of the PDE4 activity in control cells. Forskolin treatment led to a marked decrease of this novel PDE4A species and allowed the detection of a strong signal for an approximately 67 kDa PDE4D species, suggested to be PDE4D1, but did not induce PDE4B and PDE4C isoforms. Elevation of intracellular cAMP concentrations in Jurkat T-cells thus exerts a highly selective effect on the transcriptional activity of the genes encoding the various PDE4 isoforms. This leads to the down-regulation of a novel PDE4A splice variant and the induction of PDE4D1 and PDE4D2 splice variants, leading to a net increase in the total PDE4 activity of Jurkat T-cells.

Full Text

The Full Text of this article is available as a PDF (618.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anastassiou E. D., Paliogianni F., Balow J. P., Yamada H., Boumpas D. T. Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2R alpha gene expression at multiple levels. J Immunol. 1992 May 1;148(9):2845–2852. [PubMed] [Google Scholar]
  2. Anderson N. G., Kilgour E., Houslay M. D. Subcellular localization and hormone sensitivity of adipocyte cyclic AMP phosphodiesterase. Biochem J. 1989 Sep 15;262(3):867–872. doi: 10.1042/bj2620867. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ashton M. J., Cook D. C., Fenton G., Karlsson J. A., Palfreyman M. N., Raeburn D., Ratcliffe A. J., Souness J. E., Thurairatnam S., Vicker N. Selective type IV phosphodiesterase inhibitors as antiasthmatic agents. The syntheses and biological activities of 3-(cyclopentyloxy)-4-methoxybenzamides and analogues. J Med Chem. 1994 May 27;37(11):1696–1703. doi: 10.1021/jm00037a021. [DOI] [PubMed] [Google Scholar]
  4. Bach M. A., Fournier C., Bach J. F. Regulation of theta-antigen expression by agents altering cyclic AMP level and by thymic factor. Ann N Y Acad Sci. 1975 Feb 28;249:316–327. doi: 10.1111/j.1749-6632.1975.tb29079.x. [DOI] [PubMed] [Google Scholar]
  5. Beavo J. A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev. 1995 Oct;75(4):725–748. doi: 10.1152/physrev.1995.75.4.725. [DOI] [PubMed] [Google Scholar]
  6. Bolger G. B., McPhee I., Houslay M. D. Alternative splicing of cAMP-specific phosphodiesterase mRNA transcripts. Characterization of a novel tissue-specific isoform, RNPDE4A8. J Biol Chem. 1996 Jan 12;271(2):1065–1071. doi: 10.1074/jbc.271.2.1065. [DOI] [PubMed] [Google Scholar]
  7. Bolger G. B. Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes. Cell Signal. 1994 Nov;6(8):851–859. doi: 10.1016/0898-6568(94)90018-3. [DOI] [PubMed] [Google Scholar]
  8. Bolger G., Michaeli T., Martins T., St John T., Steiner B., Rodgers L., Riggs M., Wigler M., Ferguson K. A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol Cell Biol. 1993 Oct;13(10):6558–6571. doi: 10.1128/mcb.13.10.6558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1006/abio.1976.9999. [DOI] [PubMed] [Google Scholar]
  10. Chen D., Rothenberg E. V. Interleukin 2 transcription factors as molecular targets of cAMP inhibition: delayed inhibition kinetics and combinatorial transcription roles. J Exp Med. 1994 Mar 1;179(3):931–942. doi: 10.1084/jem.179.3.931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Conti M., Nemoz G., Sette C., Vicini E. Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocr Rev. 1995 Jun;16(3):370–389. doi: 10.1210/edrv-16-3-370. [DOI] [PubMed] [Google Scholar]
  12. Cook S. J., McCormick F. Inhibition by cAMP of Ras-dependent activation of Raf. Science. 1993 Nov 12;262(5136):1069–1072. doi: 10.1126/science.7694367. [DOI] [PubMed] [Google Scholar]
  13. Engels P., Sullivan M., Müller T., Lübbert H. Molecular cloning and functional expression in yeast of a human cAMP-specific phosphodiesterase subtype (PDE IV-C). FEBS Lett. 1995 Jan 30;358(3):305–310. doi: 10.1016/0014-5793(94)01460-i. [DOI] [PubMed] [Google Scholar]
  14. Gettys T. W., Vine A. J., Simonds M. F., Corbin J. D. Activation of the particulate low Km phosphodiesterase of adipocytes by addition of cAMP-dependent protein kinase. J Biol Chem. 1988 Jul 25;263(21):10359–10363. [PubMed] [Google Scholar]
  15. Horton Y. M., Sullivan M., Houslay M. D. Molecular cloning of a novel splice variant of human type IVA (PDE-IVA) cyclic AMP phosphodiesterase and localization of the gene to the p13.2-q12 region of human chromosome 19 [corrected]. Biochem J. 1995 Jun 1;308(Pt 2):683–691. doi: 10.1042/bj3080683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hsueh Y. P., Lai M. Z. c-Jun N-terminal kinase but not mitogen-activated protein kinase is sensitive to cAMP inhibition in T lymphocytes. J Biol Chem. 1995 Jul 28;270(30):18094–18098. doi: 10.1074/jbc.270.30.18094. [DOI] [PubMed] [Google Scholar]
  17. Häfner S., Adler H. S., Mischak H., Janosch P., Heidecker G., Wolfman A., Pippig S., Lohse M., Ueffing M., Kolch W. Mechanism of inhibition of Raf-1 by protein kinase A. Mol Cell Biol. 1994 Oct;14(10):6696–6703. doi: 10.1128/mcb.14.10.6696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kammer G. M. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol Today. 1988 Jul-Aug;9(7-8):222–229. doi: 10.1016/0167-5699(88)91220-0. [DOI] [PubMed] [Google Scholar]
  19. Kaye J., Ellenberger D. L. Differentiation of an immature T cell line: a model of thymic positive selection. Cell. 1992 Oct 30;71(3):423–435. doi: 10.1016/0092-8674(92)90512-b. [DOI] [PubMed] [Google Scholar]
  20. Kilgour E., Anderson N. G., Houslay M. D. Activation and phosphorylation of the 'dense-vesicle' high-affinity cyclic AMP phosphodiesterase by cyclic AMP-dependent protein kinase. Biochem J. 1989 May 15;260(1):27–36. doi: 10.1042/bj2600027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  22. Loughney K., Martins T. J., Harris E. A., Sadhu K., Hicks J. B., Sonnenburg W. K., Beavo J. A., Ferguson K. Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3',5'-cyclic nucleotide phosphodiesterases. J Biol Chem. 1996 Jan 12;271(2):796–806. doi: 10.1074/jbc.271.2.796. [DOI] [PubMed] [Google Scholar]
  23. Macphee C. H., Reifsnyder D. H., Moore T. A., Lerea K. M., Beavo J. A. Phosphorylation results in activation of a cAMP phosphodiesterase in human platelets. J Biol Chem. 1988 Jul 25;263(21):10353–10358. [PubMed] [Google Scholar]
  24. Manganiello V. C., Murata T., Taira M., Belfrage P., Degerman E. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch Biochem Biophys. 1995 Sep 10;322(1):1–13. doi: 10.1006/abbi.1995.1429. [DOI] [PubMed] [Google Scholar]
  25. Manganiello V. C., Taira M., Degerman E., Belfrage P. Type III cGMP-inhibited cyclic nucleotide phosphodiesterases (PDE3 gene family). Cell Signal. 1995 Jul;7(5):445–455. doi: 10.1016/0898-6568(95)00017-j. [DOI] [PubMed] [Google Scholar]
  26. Marchmont R. J., Houslay M. D. A peripheral and an intrinsic enzyme constitute the cyclic AMP phosphodiesterase activity of rat liver plasma membranes. Biochem J. 1980 May 1;187(2):381–392. doi: 10.1042/bj1870381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. McLaughlin M. M., Cieslinski L. B., Burman M., Torphy T. J., Livi G. P. A low-Km, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain. Cloning and expression of cDNA, biochemical characterization of recombinant protein, and tissue distribution of mRNA. J Biol Chem. 1993 Mar 25;268(9):6470–6476. [PubMed] [Google Scholar]
  28. McPhee I., Pooley L., Lobban M., Bolger G., Houslay M. D. Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family. Biochem J. 1995 Sep 15;310(Pt 3):965–974. doi: 10.1042/bj3100965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Michaeli T., Bloom T. J., Martins T., Loughney K., Ferguson K., Riggs M., Rodgers L., Beavo J. A., Wigler M. Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae. J Biol Chem. 1993 Jun 15;268(17):12925–12932. [PubMed] [Google Scholar]
  30. Michie A. M., Lobban M., Müller T., Harnett M. M., Houslay M. D. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram. Cell Signal. 1996 Feb;8(2):97–110. doi: 10.1016/0898-6568(95)02032-2. [DOI] [PubMed] [Google Scholar]
  31. Méry P. F., Pavoine C., Pecker F., Fischmeister R. Erythro-9-(2-hydroxy-3-nonyl)adenine inhibits cyclic GMP-stimulated phosphodiesterase in isolated cardiac myocytes. Mol Pharmacol. 1995 Jul;48(1):121–130. [PubMed] [Google Scholar]
  32. Nicholson C. D., Shahid M. Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes--their potential utility in the therapy of asthma. Pulm Pharmacol. 1994 Feb;7(1):1–17. doi: 10.1006/pulp.1994.1001. [DOI] [PubMed] [Google Scholar]
  33. Némoz G., Zhang R., Sette C., Conti M. Identification of cyclic AMP-phosphodiesterase variants from the PDE4D gene expressed in human peripheral mononuclear cells. FEBS Lett. 1996 Apr 8;384(1):97–102. doi: 10.1016/0014-5793(96)00300-6. [DOI] [PubMed] [Google Scholar]
  34. O'Connell J. C., McCallum J. F., McPhee I., Wakefield J., Houslay E. S., Wishart W., Bolger G., Frame M., Houslay M. D. The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5). Biochem J. 1996 Aug 15;318(Pt 1):255–261. doi: 10.1042/bj3180255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Podzuweit T., Nennstiel P., Müller A. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine. Cell Signal. 1995 Sep;7(7):733–738. doi: 10.1016/0898-6568(95)00042-n. [DOI] [PubMed] [Google Scholar]
  36. Rubin C. S. A kinase anchor proteins and the intracellular targeting of signals carried by cyclic AMP. Biochim Biophys Acta. 1994 Dec 30;1224(3):467–479. [PubMed] [Google Scholar]
  37. Scott J. D., McCartney S. Localization of A-kinase through anchoring proteins. Mol Endocrinol. 1994 Jan;8(1):5–11. doi: 10.1210/mend.8.1.8152430. [DOI] [PubMed] [Google Scholar]
  38. Sette C., Vicini E., Conti M. The ratPDE3/IVd phosphodiesterase gene codes for multiple proteins differentially activated by cAMP-dependent protein kinase. J Biol Chem. 1994 Jul 15;269(28):18271–18274. [PubMed] [Google Scholar]
  39. Shakur Y., Wilson M., Pooley L., Lobban M., Griffiths S. L., Campbell A. M., Beattie J., Daly C., Houslay M. D. Identification and characterization of the type-IVA cyclic AMP-specific phosphodiesterase RD1 as a membrane-bound protein expressed in cerebellum. Biochem J. 1995 Mar 15;306(Pt 3):801–809. doi: 10.1042/bj3060801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Smith C. J., Vasta V., Degerman E., Belfrage P., Manganiello V. C. Hormone-sensitive cyclic GMP-inhibited cyclic AMP phosphodiesterase in rat adipocytes. Regulation of insulin- and cAMP-dependent activation by phosphorylation. J Biol Chem. 1991 Jul 15;266(20):13385–13390. [PubMed] [Google Scholar]
  41. Spence S., Rena G., Sullivan M., Erdogan S., Houslay M. D. Receptor-mediated stimulation of lipid signalling pathways in CHO cells elicits the rapid transient induction of the PDE1B isoform of Ca2+/calmodulin-stimulated cAMP phosphodiesterase. Biochem J. 1997 Jan 1;321(Pt 1):157–163. doi: 10.1042/bj3210157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Spence S., Rena G., Sweeney G., Houslay M. D. Induction of Ca2+/calmodulin-stimulated cyclic AMP phosphodiesterase (PDE1) activity in Chinese hamster ovary cells (CHO) by phorbol 12-myristate 13-acetate and by the selective overexpression of protein kinase C isoforms. Biochem J. 1995 Sep 15;310(Pt 3):975–982. doi: 10.1042/bj3100975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Sullivan M., Egerton M., Shakur Y., Marquardsen A., Houslay M. D. Molecular cloning and expression, in both COS-1 cells and S. cerevisiae, of a human cytosolic type-IVA, cyclic AMP specific phosphodiesterase (hPDE-IVA-h6.1). Cell Signal. 1994 Sep;6(7):793–812. doi: 10.1016/0898-6568(94)00039-5. [DOI] [PubMed] [Google Scholar]
  44. Swinnen J. V., Joseph D. R., Conti M. The mRNA encoding a high-affinity cAMP phosphodiesterase is regulated by hormones and cAMP. Proc Natl Acad Sci U S A. 1989 Nov;86(21):8197–8201. doi: 10.1073/pnas.86.21.8197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Swinnen J. V., Tsikalas K. E., Conti M. Properties and hormonal regulation of two structurally related cAMP phosphodiesterases from the rat Sertoli cell. J Biol Chem. 1991 Sep 25;266(27):18370–18377. [PubMed] [Google Scholar]
  46. Thompson W. J., Appleman M. M. Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry. 1971 Jan 19;10(2):311–316. [PubMed] [Google Scholar]
  47. Thompson W. J. Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function. Pharmacol Ther. 1991;51(1):13–33. doi: 10.1016/0163-7258(91)90039-o. [DOI] [PubMed] [Google Scholar]
  48. Torphy T. J., Barnette M. S., Hay D. W., Underwood D. C. Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma. Environ Health Perspect. 1994 Dec;102 (Suppl 10):79–84. doi: 10.1289/ehp.94102s1079. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Torphy T. J., Zhou H. L., Foley J. J., Sarau H. M., Manning C. D., Barnette M. S. Salbutamol up-regulates PDE4 activity and induces a heterologous desensitization of U937 cells to prostaglandin E2. Implications for the therapeutic use of beta-adrenoceptor agonists. J Biol Chem. 1995 Oct 6;270(40):23598–23604. doi: 10.1074/jbc.270.40.23598. [DOI] [PubMed] [Google Scholar]
  50. Verghese M. W., McConnell R. T., Lenhard J. M., Hamacher L., Jin S. L. Regulation of distinct cyclic AMP-specific phosphodiesterase (phosphodiesterase type 4) isozymes in human monocytic cells. Mol Pharmacol. 1995 Jun;47(6):1164–1171. [PubMed] [Google Scholar]
  51. Whetton A. D., Needham L., Dodd N. J., Heyworth C. M., Houslay M. D. Forskolin and ethanol both perturb the structure of liver plasma membranes and activate adenylate cyclase activity. Biochem Pharmacol. 1983 May 15;32(10):1601–1608. doi: 10.1016/0006-2952(83)90334-9. [DOI] [PubMed] [Google Scholar]
  52. Wilson M., Sullivan M., Brown N., Houslay M. D. Purification, characterization and analysis of rolipram inhibition of a human type-IVA cyclic AMP-specific phosphodiesterase expressed in yeast. Biochem J. 1994 Dec 1;304(Pt 2):407–415. doi: 10.1042/bj3040407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Wu H., Parsons J. T. Cortactin, an 80/85-kilodalton pp60src substrate, is a filamentous actin-binding protein enriched in the cell cortex. J Cell Biol. 1993 Mar;120(6):1417–1426. doi: 10.1083/jcb.120.6.1417. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES